Comparative Pharmacology
Head-to-head clinical analysis: METROGEL versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROGEL versus METROLOTION.
METROGEL vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)